Are we reading different releases, this is only a daily dose trial. Standard treatment is 3x daily. P values at 3x are way better
"Having demonstrated protective efficacy in two published clinical studies (Otto et al., 2011), this Phase 2 study wasdesigned to compare the preventative effects of once daily dosing to the current standard recommended treatmentof three times daily dosing."
"Travelan® demonstrated clinical efficacy in preventing ETEC-attributable diarrhea in two previous CHIM studies. Thesestudies showed dosing 400 mg three times daily, resulted in 76.7% (p=0.007) to 90.9% (p=0.0005) protection (Otto etal., 2011)."
IMC Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
